Sollis Therapeutics is a clinical-stage biotechnology company focused on novel non-steroid, non-opioid analgesics for neuropathic pain such as sciatica. Its lead product is an extended-release combination analgesic and anti-inflammatory designed for targeted local delivery to treat low back and leg pain from sciatica. The company has reported positive results from prior clinical studies and was recently awarded a grant from Ohio Third Frontier’s Opioid Technology Challenge. Proceeds from the announced funding will be used to initiate and complete a US pivotal clinical study, pursue FDA submission for sciatica, and develop additional pipeline products. NIT founded Sollis in 2017 and has provided capital and management expertise to advance its clinical application. Sollis is headquartered in Columbus, Ohio and is positioning a non-opioid, locally delivered therapy as an alternative to systemic opioids and injected steroids.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2018